Clinical Laboratory Evaluation of Organ and Systemic Diseases
This domain integrates organ-specific testing. Renal: creatinine, cystatin C, BUN, urinalysis, and the distinction between prerenal, intrinsic, and postrenal azotemia (BUN-to-creatinine ratio, fractional excretion of sodium). Liver: transaminases (hepatocellular), alkaline phosphatase and GGT (cholestatic), bilirubin, albumin, and coagulation. Cardiac: troponin (high-sensitivity), CK-MB, BNP, and the timing of marker release.
Endocrine: thyroid function (TSH, free T4, total T4 with binding proteins), adrenal testing (cortisol, ACTH stimulation), and reproductive hormones. Pancreatic: amylase and lipase (lipase more specific). Gastrointestinal and tumor markers have limited screening value.
Pregnancy and newborn: hCG interpretation (discordant results, heterophile antibodies), gestational diabetes screening, and newborn screening. Point-of-care testing and infectious disease serology are covered separately but integrate here.
Worked example: a patient with elevated AST/ALT, mildly elevated alkaline phosphatase, and prolonged INR suggests hepatocellular injury with synthetic dysfunction; check for acetaminophen and viral hepatitis.
Trap: using BUN-to-creatinine ratio alone to classify azotemia-it is suggestive, not definitive.
Reproduction, Pregnancy, and Newborn Screening and Monitoring
Understand the menstrual cycle hormonal patterns and their laboratory correlates: FSH and LH surge at midcycle, progesterone rise in the luteal phase, and the use of serial hCG in early pregnancy. hCG doubles approximately every 48 hours in normal early pregnancy; a suboptimal rise suggests ectopic or nonviable pregnancy. Heterophile antibodies and hook effects cause false hCG results.
Prenatal screening: first-trimester combined screening (PAPP-A, free beta-hCG, nuchal translucency), second-trimester quad screen (AFP, hCG, unconjugated estriol, inhibin A), and cell-free DNA. Understand that screening tests estimate risk, not diagnosis; abnormal screens require diagnostic testing (amniocentesis, CVS).
Newborn screening: state panels vary but typically include congenital hypothyroidism, PKU, galactosemia, sickle cell disease, cystic fibrosis, and congenital adrenal hyperplasia. Timing (24–72 hours of life), prematurity, and transfusion affect results. Confirmatory testing is mandatory.
Worked example: a newborn screen shows elevated 17-hydroxyprogesterone; consider congenital adrenal hyperplasia (21-hydroxylase deficiency) and confirm with repeat testing and electrolytes.
Trap: interpreting a screening test as diagnostic, or forgetting that newborn transfusion can mask hemoglobin disorders.
Point-of-Care Testing
POCT brings testing to the patient but requires the same quality standards as central laboratory testing. Know the regulatory framework: waived tests under CLIA, operator training, competency assessment, and device maintenance. POCT devices must be validated before use and correlated with central laboratory methods.
Common POCT: glucose, blood gas, coagulation (INR), cardiac markers, urine dipstick, and infectious disease rapid tests. Understand limitations: operator-dependent error, environmental effects, and narrower analytic ranges. Glucose meters are affected by hematocrit, altitude, and interfering substances; critically ill patients may have inaccurate results.
Quality management for POCT: internal QC, external proficiency testing (where applicable), documentation of operator competency, and connectivity to the laboratory information system. Understand the concept of a POCT coordinator and oversight by the laboratory director.
Worked example: a glucose meter reading of 40 mg/dL in a patient without hypoglycemic symptoms should be confirmed by laboratory glucose before treatment, especially if the meter has not had QC performed.
Trap: assuming waived status means no quality oversight-training, QC, and documentation are still required.
Infectious Disease Serology and Disorders of the Immune System
Understand serologic test principles: sensitivity, specificity, predictive values, and the effect of prevalence. IgM versus IgG indicates acute versus past infection, but IgM can persist and cross-react. Window periods and confirmatory testing (Western blot, nucleic acid testing) are essential.
Know common serologic patterns: hepatitis B (surface antigen, core antibody IgM/IgG, surface antibody, e抗原), hepatitis C (antibody screening with reflex RNA), HIV (antigen/antibody combination with reflex differentiation), syphilis (nontreponemal RPR/VDRL with treponemal confirmation), and Epstein-Barr virus (heterophile antibody, viral capsid antigen).
Immune disorders: primary immunodeficiencies (low immunoglobulins, absent B or T cells), complement deficiencies, and autoimmunity (ANA, anti-dsDNA, rheumatoid factor, anti-CCP). Understand that ANA is sensitive but not specific; anti-dsDNA and anti-Smith are specific for SLE.
Worked example: a patient with positive HIV antigen/antibody screen and a negative differentiation assay requires HIV-1 RNA testing to resolve the result.
Trap: interpreting a positive screening test as diagnostic without confirmatory testing, or ignoring prevalence effects on predictive value.
Toxicology, Drug Misuse, and Therapeutic Drug Monitoring
Distinguish screening immunoassays from confirmatory methods (GC-MS, LC-MS/MS). Screening tests are sensitive but not specific; confirmatory testing is required for legal or clinical decisions. Understand cutoffs, cross-reactivity (e.g., amphetamine immunoassays reacting with pseudoephedrine), and the difference between false positives and true positives.
Common toxidromes and analytes: acetaminophen (nomogram for overdose), salicylates, ethanol, methanol, ethylene glycol (osmolal gap), and drugs of abuse (opioids, cocaine metabolite, cannabinoids, benzodiazepines). Understand that urine drug screens detect metabolites and have variable detection windows.
Therapeutic drug monitoring: know drugs requiring monitoring (digoxin, lithium, phenytoin, vancomycin, aminoglycosides, cyclosporine, tacrolimus), their therapeutic ranges, and timing (trough levels). Understand pharmacokinetics: half-life, volume of distribution, and the effect of renal or hepatic impairment.
Worked example: a patient with an acetaminophen level above the Rumack-Matthew nomogram line at 4 hours after ingestion requires N-acetylcysteine.
Trap: treating a positive screen as definitive without confirmation, or drawing drug levels at the wrong time relative to dosing.
Patient Care Decision-Making and Consultation
This domain tests integration: interpreting laboratory data in clinical context, recognizing when results are discordant, and communicating with clinicians. Key skills include delta checks, critical value reporting, and recognizing preanalytic and analytic errors.
Understand reference intervals versus decision limits; reference intervals describe a population, while decision limits (e.g., glucose for diabetes) define clinical action. Recognize that a result within the reference interval can still be abnormal for a given patient (e.g., a falling hemoglobin).
Consultation concepts: test utilization (avoiding unnecessary testing), choosing the right test (e.g., free light chains versus SPEP), and interpreting panels. Understand the laboratory's role in antimicrobial stewardship and in identifying errors through quality review.
Worked example: a patient with a normal TSH but symptoms of hypothyroidism-consider assay interference (biotin, heterophile antibodies) or central hypothyroidism; free T4 and clinical correlation guide next steps.
Trap: interpreting a single value without trend or clinical context, or failing to recognize that a critical value must be reported and documented.